News
-
11 January 2021
Immunocore announces closing of $75.0 Million Series C round -
3 December 2020
Immunocore presents Phase 2 tebentafusp clinical results at ESMO Immuno-Oncology Virtual Congress 2020 -
23 November 2020
Immunocore’s tebentafusp demonstrates superior overall survival compared to investigator’s choice in a Phase 3 clinical trial of patients with previously untreated metastatic uveal melanoma -
15 October 2020
Immunocore Appoints Nobel Laureate Professor Sir Peter J. Ratcliffe as Non-Executive Director -
27 August 2020
Immunocore announces publication of preclinical data in Hepatology showing the potential of ImmTAV® bispecific molecules for functional cure of chronic hepatitis B -
26 May 2020
Immunocore announces dosing of first patient with fourth ImmTAC -
6 May 2020
Immunocore appoints Brian Di Donato as Chief Financial Officer and Head of Strategy -
4 March 2020
First Site in Global Uveal Melanoma Patient Registry Now Open -
2 March 2020
Immunocore Secures $130 Million Series B Financing -
9 December 2019
Immunocore announces dosing of first patient with third ImmTAC® bispecific